Veno-occlusive disease of the liver after hemopoietic cell transplantation

European Journal of Haematology

Volumn 64, Issue 5, 2000, Pages 281-291

  Carreras, Enric ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Hemopoietic cell transplantation; Hepatic VOD; Veno occlusive disease of the liver

Indexed keywords

ALTEPLASE; BIOLOGICAL MARKER; DEFIBROTIDE;

DIFFERENTIAL DIAGNOSIS; FLUID RETENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; JAUNDICE; LIVER VENOOCCLUSIVE DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WEIGHT GAIN;

FIBRINOLYTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; POLYDEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034025640     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.9r200.x     Document Type: Review

References (122)

1. 1. SELZER G, PARKER RGF. Senecio poisoning exhibiting as Chiari's syndrome. Am J Pathol 1951;27:885-907.
2. 2. VALLA D, BENHAMOU JP. Disorders of the Hepatic veins and venules. In: MCINTYRE N, BENHAMOU JP, BIRCHER J, RIZZETTO M, RODÉS J, eds. Oxford Textbook of Clinical Hepatology, vol. 2. Oxford: Oxford University Press, 1991: 1004-1011.
3. 3. JACOBS P, MILLER JL, UYS CJ, DIETRICH BE. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukemia. S Afr Med J 1979;55:5-10.
4. 4. SHULMAN HM, HINTERBERGER W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1982;10:197-214.
5. 5. MCDONALD GB, SHULMAN HM, WOLFORD JL, SPENCER GD. Liver disease after human marrow transplantation. Semin Liv Dis 1987;7:210-229.
6. 6. CARRERAS E, GRAÑENA A, ROZMAN C. Hepatic veno-occlusive disease after bone marrow transplant. Blood Rev 1993;7:43-51.
7. 7. BEARMAN SJ. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85: 3005-3020.
8. 8. CARRERAS E, ROZMAN C. The syndrome of veno-occlusive disease after blood or marrow transplantation. Hematology 1998;3:303-314.
9. 9. STRASSER SI, MCDONALD GB. Gastrointestinal and hepatic complications. In: THOMAS ED, BLUME KG, FORMAN SJ, eds. Hemopoietic cell transplantation, 2nd edn. Malden: Blackwell Science, 1999:627-658.
10. 10. MCDONALD GB, HINDS MS, FISHER LD, et al. Veno-occlusive disease of the liver and multiorgan failure after Bone Marrow Transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
11. 11. RICHARDSON P, GUINAN E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999;107:485-493.
12. 12. HARPER PL, JARVIS J, JENNINGS I, LUDDINGTON R, MARCUS RE. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5:39-42.
13. 13. GORDON B, HAIRE W, KESSINGER A, DUGGAN M, ARMITAGE J. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991;8:497-502.
14. 14. COLLINS P, JONE B, UTHAYAKUMAR S, et al. Haemostatic changes in uncomplicated bone marrow transplantation. Bone Marrow Transplant 1991;7(suppl 2):54.
15. 15. SCROBOHACI ML, DROUET L, MONEM-MANSI A, et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991;63:509-519.
16. 16. FAIONI EM, BEARMAN SI, KRACHMALNICOFF A, et al. Procoagulant inbalance due to low levels of protein C in patients with venocclusive disease (VOD) of the liver after bone marrow transplantation. Blood 1991;78:193a.
17. 17. CATANI L, GUGLIOTTA L, MATTIOLI M, VIANELLI N, GHERLINZONI F, MIGGIANO MC. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant 1993;12:253-259.
18. 18. COLLINS P, RODERICK A, O'BRIEN D, et al. Factor VIIa and other hemostatic variables following bone marrow transplantation. Thrombosis & Haemostasis 1994;72:28-32.
19. 19. VANNUCCHI AM, RAFANELLI D, LONGO G, et al. Early hemostatic alterations following bone marrow transplantation: a prospective study. Haematologica 1994;19:519-525.
20. 20. FAIONI EM, MANNUCCI PM. Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis. Leuk Lymphoma 1997;25:233-245.
21. 21. SALAT C, HOLLER E, KOLB HJ, et al. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Leuk Lymphoma 1999;33:25-32.
22. 22. SALAT C, HOLLER E, KOLB HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997;89: 2184-2188.
23. 23. SHULMAN HM, LUK K, DEEG HJ, SHUMAN WB, STORB R. Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 1987;126:114-125.
24. 24. LEBREC D, BENHAMOU JP. Noncirrhotic intrahepatic portal hypertension. Semin Liver Dis 1986;6:332-340.
25. 25. SHULMAN HM, GOWN AM, NUGENT DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occlude central venules. Am J Pathol 1987;127: 549-558.
26. 26. SHULMAN HM, FISHER LB, SCHOCK HG, KENNE KW, MCDONALD GB. Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1984;19:1171-1180.
27. 27. HOLLER E, KOLB HJ, MÖLLER A, et al. Increased serum levels of tumor necrosis factor precede major complications of bone marrow transplantation. Blood 1990;75: 1011-1016.
28. 28. BAUER KA, CATE H, BARZEGAR S, SPRIGGS DR, SHERMAN ML, ROSENBERG RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1990;75:165-168.
29. 29. NAWROTH PP, HANDLEY DA, ESMON CT, STERN DM. Interleukin-1 induces modulation of endothelial cells procoagulant while suppressing cell surface anticoagulant activity. Proc Nat Acad Sci USA 1986;83:3460-3464.
30. 30. BAARS JW, DE BOER JP, WAGSTAFF J, et al. Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to changes seen during experimental endotoxaemia. Br J Haematol 1992;82:295-301.
31. 31. BAKER LRI, TUCKER B, KOVACS IB. Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. Transplantation 1990; 49:905-909.
32. 32. FARRAND AL, NASH RA, ZAGER RA, GMUR D, MCDONALD GB. Pathogenesis of venocclusive disease of the liver. Role of cytokines, NO, endothelin-1 and fibrosis. Gastroenterology 1996;110:1189a.
33. 33. MCDONALD GB, SHARMA P, MATTHEWS DE, SHULMAN HM, THOMAS ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984;4:116-122.
34. 34. CARRERAS E, VIGURIA MC, ROVIRA M, et al. Veno-occlusive disease of the liver after allogeneic blood and marrow transplantation: A retrospective analysis of 376 consecutive BMT performed in a single center. Bone Marrow Transplant 1998;21(suppl 1):S239.
35. 35. BERK PD, POPPER H, KRUEGER GRF, DECTER J, HERZIG G, GRAW R. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Possible association with graft versus host disease. Ann Intern Med 1979;90:158-164.
36. 36. SOIFFER RJ, DEAR K, RABINOWE SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991;52:1014-1019.
37. 37. ANSCHER MS, PETERS WP, REISENBICHLER H, PETROS WP, JIRTLE RL. Transforming growth factor B as predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-1598.
38. 38. CARRERAS E, BERTZ H, ARCESE W, et al. Incidence and outcome of hepatic veno-occlusive disease (VOD) after blood and marrow transplantation (BMT): a prospective cohort study of the European group for Blood and Marrow Transplantation (EBMT). Blood 1998;92:3599-3604.
39. 39. ROZMAN C, CARRERAS E, QIAN C, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling marrow transplants for leukemia. Bone Marrow Transplant 1996;17:75-80.
40. 40. RADICH JP, SANDERS JE, BUCKNER CD, et al. Second bone marrow transplantation for patients with recurrent leukemia after initial transplant with TBI-containing regimens. J Clin Oncol 1993;11:304-313.
41. 41. STRASSER SI, MYERSON D, SPURGEON CL, et al. Hepatitis C virus infection after bone marrow transplantation. A cohort study with 10 years follow-up. Hepatology 1999;29:1893-1899.
42. 42. LUCARELLI G, POLCHI P, GALIMBERT M, et al. Marrow transplantation for thalassaemia following busulphan and cyclophosphamide. Lancet 1985;i:1355-1357.
43. 43. DELEVE LD, WANG XD, HUYBRECHTS MM. Cellular target of cyclophosphamide toxicity in the murine liver-role of glutathione and site of metabolic activation. Hepatology 1996;24:830-837.
44. 44. TEICHER BA, CRAWFORD JM, HOLDEN SA, et al. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer 1988;62:1275-1281.
45. 45. PESSAYRE D, LARREY D. Drug-induced liver injury. In: MCINTYRE N, BENHAMOU JP, BIRCHER J, RIZZETTO M, RODÉS J, eds. Oxford Textbook of Clinical Hepatology, vol. 2. Oxford: Oxford University Press, 1991:873-902.
46. 46. BRUGIERES L, HARTMANN O, BENHAMOU E, et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 1988;3:53-58.
47. 47. LEE JL, GOOLEY T, BENSINGER W, SCHIFFMAN K, MCDONALD GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999;5:306-315.
48. 48. JONES RJ, LEE KS, BESCHORNER WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-783.
49. 49. MCDONALD GB, SHARMA P, MATTHEWS DE, SHULMAN HM, THOMAS ED. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985;39:603-608.
50. 50. RIO B, ANDREU G, NICOD A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986;67:1773-1776.
51. 51. ZAGER RA, O'QUIGLEY J, ZAGER BK, et al. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989;13:210-216.
52. 52. CARRERAS E, GRAÑENA A, NAVASA M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993;66:77-80.
53. 53. SHULMAN HM, MCDONALD GB. Liver disease after bone marrow transplantation. In: SALE GE, SHULMAN HM, eds. The pathology of bone marrow transplantation. New York: Masson Inc, 1984:104-135.
54. 54. CARRERAS E, GRAÑENA A, NAVASA M, et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993;11:21-26.
55. 55. CARRERAS E, GARCÍA-PAGÁN JC, BOSCH J, ROZMAN C. Transvenous liver biopsies in marrow transplant recipients. Transplantation 1995;60:1375.
56. 56. SHULMAN HM, GOOLEY T, DUDLEY MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow recipients. Transplantation 1995;59:1015-1022.
57. 57. BROWN BP, ABU-YOUSEF M, FARNER R, LABRECQUE D, GINGRICH R. Doppler sonography: a noninvasive method for evaluation of hepatic venocclusive disease. AJR 1990; 154:721-724.
58. 58. HERBETKO J, GRIGG AP, BUCKLEY AR, PHILLIPS GL. Veno-occlusive liver disease after bone marrow transplantation: findings at duplex sonography. AJR 1992;158:1001-1005.
59. 59. NICOLAU C, BRU C, CARRERAS E, et tal. Sonographic diagnosis and hemodinamic correlation in veno-occlusive disease of the liver. J Ultras Med 1993:12:437-440.
60. 60. HOMMEYER SC, TEEFEY SA, JACOBSON AF, et al. Venocclusive disease of the liver: Prospective study of US evaluation. Radiology 1992;184:683-686.
61. 61. DEEG KH, GLOCKEL U, RICHTER R, BECK J. Diagnosis of veno-occlusive disease of the liver by color-coded Doppler sonography. Pediatr Radiol 1993;23:134-136.
62. 62. LASSAU N, LECLERE J, AUPERIN A, et al. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Radiology 1997;204:545-552.
63. 63. RIO B, BAUDUER F, ARRAGO J, ZITTOUN R. N-Terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive after BMT and basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993;11:4711-4712.
64. 64. ELTUMI M, TRIVEDI P, HOBBS JR, et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993;342:518-521.
65. 65. HEIKINHEIMO M, HALILA R, FASTH A. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994;83:3036-3040.
66. 66. HÄGGLUND H, REMBERGER M, KLAESSON S, LÖNNQVIST B, LJUNGMAN P, RINGDEN O. Noethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92:4568-4572.
67. 67. BEARMAN SI, ANDERSON GL, MORI M, HINDS MS, SHULMAN HM, MCDONALD GB. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-1736.
68. 68. BEARMAN SI, APPELBAUM FR, BUCKNER CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-1568.
69. 69. DULLEY FL, KANFER EJ, APPELBAUM FR, et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987;43: 870-873.
70. 70. GANEM G, SAINT-MARC GIRARDIN MF, KUENTZ M, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Oncol Biol Phys 1988;14:879-884.
71. 71. AYASH LJ, HUNT M, ANTMAN K, et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990;8:1699-1706.
72. 72. LOCASCIULLI A, BACIGALUPO A, ALBERTI A, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplant. Transplantation 1989; 48:68-72.
73. 73. WITHERSPOON RP, STORB R, SHULMAN HM, et al. Marrow transplantation in hepatitis-associated aplastic anemia. Am J Hematol 1984;17:269-278.
74. 74. CHEN PM, FAN S, HSIEH RK, LIU RS, TZENG CH, CHIOU TJ, LIU JH. Liver disease in patients with liver dysfunction prior to bone marrow transplantation. Bone Marrow Transplant 1992;9:415-419.
75. 75. LOCASCIULLI A, TESTA M, VALSECCHI MG, et al. The role of hepatitis C and hepatitis B virus infection as risk factors for severe liver complications following allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21(suppl 1):S147.
76. 76. DEEG HJ, SULLIVAN KM, BUCKNER CD, et al. Marrow transplantation for nonlymphophastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1986;1:151-157.
77. 77. COSSET JM, BAUME D, PICO JL, SHANK B, et al. Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy. Radiother Oncol 1989;15:151-160.
78. 78. KIM TH, MCGLAVE PB, RAMSAY N, et al. Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission. Int J Radiat Oncol Biol Phys 1990;19:889-897.
79. 79. OZSAHIN M, PÈNE F, TOUBOUL E, et al. Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients. Cancer 1992;69:2853-2865.
80. 80. VALLS A, GRAÑENA A, CARRERAS E, FERRER E, ALGARA M. Total body irradiation in bone marrow transplantation: fractionated vs. single dose. Acute toxicity and preliminary results. Bull Cancer 1989;76:797-804.
81. 81. NEVILL TJ, BARNETT MJ, KLINGEMANN HG, REECE DE, SHEPHERD JD, PHILLIPS GL. Regime related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991;9:1224-1229.
82. 82. OZKAYNAK MF, WEINBERG K, KOHN D, SENDER L, PARKMAN R, LENARSKY C. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. Bone Marrow Transplant 1991;7: 467-474.
83. 83. MERESSE V, HARTMANN O, VASSAL G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992;10:135-141.
84. 84. BEELEN DW, QUABECK K, GRAEVEN U, SAYER HG, MAHMOUD HK, SCHAEFER UW. Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood 1989;74:1507-1516.
85. 85. BRODSKY R, TOPOLSKY D, CRILLEY P, BULOVA S, BRODSKY I. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 1990;13:221-225.
86. 86. VASSAL G, HARTMANN O, BENHAMOU E. Busulfan and veno-occlusive disease of the liver. Ann Intern Med 1990;112:881.
87. 87. MORGAN M, DODDS A, ATKINSON K, SZER J, DOWNS K, BIGGS J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991;77:529-534.
88. 88. VAUGHAN WP, DENNISON JD, REED EC, et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991;8: 489-495.
89. 89. VAN DER JAGT RHC, APPELBAUM FR, PETERSEN FB, et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991;8:211-215.
90. 90. COPERLAN EA, BIGGS JC, THOMPSON JM, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991;78:838-843.
91. 91. ESSELL JH, THOMPSON JM, HARMAN GS, et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving Busulfan/Cyclophosphamide. Blood 1992;79:2784-2788.
92. 92. GROCHOW LB, JONES RJ, BRUNDRETT RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61.
93. 93. HASSAN M, EHRSSON H, LJUNGMAN P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996;22:395-407.
94. 94. YEAGER AM, WAGNER JE JR, GRAHAM ML, JONES RJ, SANTOS GW. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation. Blood 1992;80:2425-2428.
95. 95. SCHULER U, SCHROERS,KUHNLE A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994;14:759-765.
96. 96. SLATTERY JT, CLIFT RA, BUCKNER CD, et al. Marrow transplantation for chronic myeloid leukemia the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-3060.
97. 97. VASSAL G, KOSCIELNY S, CHALLINE D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996;37:247-253.
98. 98. SULLIVAN KM, KANSU E, STORER B, et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol Blood Marrow Transplant 1998;4:20-26.
99. 99. MARSA-VILA L, GORIN NC, LAPORTE JP, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991;47:346-354.
100. 100. ATTAL M, HUGUET F, RUBIE H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992;79:2834-2840.
101. 101. ROSENTHAL J, SENDER L, SECCOLA R, et al. Phase II trial of heparin prophylaxis for veno-occlusive of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996;18:185-191.
102. 102. BEARMAN SI, HINDS MS, WOLFORD JL, et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990;5:407-411.
103. 103. OR O, NAGLER A, SHPILBERG O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996;61:1067-1071.
104. 104. GLUCKMAN E, JOLIVET I, SCROBOHACI ML, et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990:74:277-281.
105. 105. BEARMAN SI, HINDS MS, MCDONALD GB. Prostaglandin E1 for prevention of hepatic veno-occlusive disease: results of a phase I study. Exp Hematol 1991;19:567.
106. 106. DEMUYNCK H, VANDENBERGHE P, VERHOEF GEC, ZACHEE P, BOOGAERTS MA. Prevention of veno-occlusive disease of the liver after marrow and blood progenitor cells transplantation: A prospective, randomized study of different prophylactic regimes. Blood 1995;86:620a.
107. 107. ESSELL JH, SCHROEDER M, HARMAN GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic stem cell transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:975-981.
108. 108. RUUTU T, ERIKSSON B, REMES K, et al. Ursodiol for the prevention of hepatic complications in allogeneic stem cell transplantation. Bone Marrow Transplant 1999;23:756.
109. 109. ATTAL M, HUGUET F, RUBIE H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82:732-736.
110. 110. CLIFT RA, BIANCO JA, APPELBAUM FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993:82:2025-2030.
111. 111. BACQ Y, GAUDIN C, HADENGUE A, ROULOT D, BRAILLON A, MOREAU R, LEBREC D. Systemic, splanchnic and renal hemodinamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology 1991;14:483-487.
112. 112. IBRAHIM A, PICO PL, MARANINCHI D, et al. Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. Bone Marrow Transplant 1991;7(supp2):53.
113. 113. ZABELINA T, KROGER N, KRUGER W, et al. Prostaglandine E1 for treatment of VOD in patients undergoing stem cell transplantation from unrelated donors. Bone Marrow Transplant 1999;23:758a.
114. 114. BEARMAN SI, LEE JL, BARÓN AE, MACDONALD GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501-1506.
115. 115. RICHARDSON P, ELIAS D, KRISHNAN A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in efficacy without significant toxicity in a high risk population. Blood 1998;92:737-744.
116. 116. MORRIS JD, HARRIS RE, HASHMI R, et al. Antithombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997;20:871-878.
117. 117. HAIRE WD, RUBY EI, STEPHENS LC, et al. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfuntion syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 1998;4:142-150.
118. 118. DE LA RUBIA J, CARRAL A, MONTES H, URQUIJO JJ, SANZ GF, SANZ MA. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS). Haematologica 1996;81:536-539.
119. 119. FRIED MW, CONNAGHAN DG, SHARMA S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe veno-occlusive disease after bone marrow transplantation. Hepatology 1996;24:588-591.
120. 120. SMITH FO, JOHNSON MS, SCHERER LR, et al. Transjugular intrahepatic portosystemic shunting for treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996;18:643-646.
121. 121. NIMER SD, MILEWICZ AL, CHAMPLIN RE, BUSUTTIL RW. Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 1990;49:819-821.
122. 122. RAPPAPORT AP, DOYLE HR, STARZL T, ROWE JM, DOEBLIN T, DIPERSIO JF. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 1991;8:421-424.